 The study uses the Ocular Bandage Gel OBG eye drop to treat patients with PE and is evaluating several different exploratory performance endpoints. Following data from this study, which is expected by the end of the first quarter of 2020, EyeGate plans to meet with the FDA to discuss the results and confirm the most ideal endpoint to use in the pivotal study. EyeGates lead product, Ocular Bandage Gel OBG, is based on a modified form of the natural polymer hyaluronic acid, which is a gel that possesses unique properties providing hydration and healing when applied to the ocular surface. 